Autoimmune disorders stem cell therapy - CYTORA
Latest Information Update: 05 Mar 2026
At a glance
- Originator CYTORA
- Class Antipsoriatics; Skin disorder therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Psoriasis
Most Recent Events
- 05 Mar 2026 Cytora has patent protection for hOMSC technology platform worldwide (Cytora website, March 2026)
- 05 Mar 2026 Preclinical trials in Autoimmune disorders in United Kingdom (Parenteral), prior to March 2026 (Cytora website, March 2026)
- 05 Mar 2026 Preclinical trials in Psoriasis in United Kingdom (Parenteral), prior to March 2026 (Cytora website, March 2026)